Aker BioMarine ASA (OSL:AKBM)
Norway · Delayed Price · Currency is NOK 110.00
+6.00 (5.77%)
Jul 31, 2026, 4:25 PM CET
Aker BioMarine ASA Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 19.7 | 16.9 | 15 | 27.5 | 22.3 | 11.1 |
Cash & Short-Term Investments | 19.7 | 16.9 | 15 | 27.5 | 22.3 | 11.1 |
Cash Growth | 1.03% | 12.67% | -45.45% | 23.32% | 100.90% | 3.95% |
Accounts Receivable | 51.1 | 47.3 | 54.2 | 71.5 | 68.8 | 77.7 |
Other Receivables | 1.5 | 1.4 | 0.9 | 0.3 | - | - |
Total Trade Receivables | 52.6 | 48.7 | 55.1 | 71.8 | 68.8 | 77.7 |
Inventory | 123.7 | 107.2 | 89.3 | 183.7 | 196.6 | 138.2 |
Other Current Assets | 9 | 25.5 | 35.3 | 7.1 | 11 | 12.5 |
Total Current Assets | 205.1 | 198.4 | 194.8 | 290.2 | 298.7 | 239.5 |
Net Property, Plant & Equipment | 60.3 | 56.3 | 51.6 | 350.6 | 343.1 | 339.2 |
Other Intangible Assets | 118 | 116.9 | 123.4 | 155.4 | 162.7 | 171.5 |
Long-Term Investments | 1.5 | 2.2 | 0.4 | 0.1 | 10.2 | 0.1 |
Other Long-Term Assets | 12.2 | 15 | 10.2 | 30.9 | 7.7 | 7.2 |
Total Assets | 397 | 388.9 | 380.4 | 827.1 | 822.4 | 757.5 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 49 | 50.9 | 42.6 | 63.9 | 57.1 | 46.6 |
Current Portion of Long-Term Debt | 27.2 | 22.9 | 7.2 | 49 | 47.6 | 30.7 |
Other Current Liabilities | 2.7 | 3.4 | 3.4 | - | - | - |
Total Current Liabilities | 78.9 | 77.2 | 53.2 | 112.9 | 104.7 | 77.3 |
Long-Term Debt | 177.6 | 159.3 | 140.3 | 344 | 333.6 | 294.1 |
Other Long-Term Liabilities | 4.4 | 8.5 | 20.1 | 3.7 | 5.5 | 15.7 |
Total Long-Term Liabilities | 182.1 | 167.8 | 160.3 | 347.7 | 339 | 309.8 |
Total Liabilities | 261 | 245 | 213.6 | 460.6 | 443.7 | 387.1 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 75.9 | 75.9 | 75.9 | 75.9 | 75.9 | 75.9 |
Additional Paid-in Capital | 494.1 | 494 | 494 | 493.8 | 493.7 | 493.6 |
Accumulated Other Comprehensive Income | -0.1 | -0.1 | -0.1 | 0.1 | 3.5 | 5.4 |
Retained Earnings | -434.1 | -425.9 | -403.3 | -203.3 | -194.4 | -204.4 |
Total Common Shareholders' Equity | 135.8 | 143.9 | 166.5 | 366.5 | 378.7 | 370.5 |
Shareholders' Equity | 135.9 | 143.9 | 166.9 | 366.5 | 378.7 | 370.4 |
Total Liabilities & Equity | 397 | 388.9 | 380.4 | 827.1 | 822.4 | 757.5 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 204.8 | 182.2 | 147.5 | 393 | 381.2 | 324.8 |
Net Cash (Debt) | -185.1 | -165.3 | -132.5 | -365.5 | -358.9 | -313.7 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -1.80 | -1.89 | -1.51 | -4.17 | -4.10 | -3.58 |
Book Value | 135.8 | 143.9 | 166.5 | 366.5 | 378.7 | 370.5 |
Book Value Per Share | 1.32 | 1.64 | 1.90 | 4.18 | 4.32 | 4.23 |
Tangible Book Value | 17.8 | 27 | 43.1 | 211.1 | 216 | 199 |
Tangible Book Value Per Share | 0.17 | 0.31 | 0.49 | 2.41 | 2.46 | 2.27 |